The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Meningococcal disease remains a major global cause of meningitis and septicaemia. In Europe and other industrialised countries, serogroup B (MenB) is responsible for most cases of invasive ...

GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal ...

The Food and Drug Administration (FDA) has approved Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis ...

The Food and Drug Administration (FDA) has approved Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

Hundreds have already taken advantage of the CLP’s free meningococcal B vaccination program, which provides protection for infants aged six weeks to two years, and teens aged 14 to 19 years.

Single component serogroup B OMV vaccines have been used in meningococcal serogroup B outbreak settings and appear to be safe and effective. 41-45 The multicomponent meningococcal vaccine (4CMenB) ...

GSK’s Meningococcal Group B Vaccine has been licensed in over 40 countries, including member states of the European Union, Argentina, Australia, Canada, Chile, Israel, New Zealand, Turkey ...